Menu Search
Equities

Akebia Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
AX9:FRA

Akebia Therapeutics Inc

Actions
  • Price (EUR)1.13
  • Today's Change-0.018 / -1.57%
  • Shares traded1.00k
  • 1 Year change-44.28%
  • Beta0.3771
Data delayed at least 15 minutes, as of Feb 09 2026 07:15 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Its HIF-based product candidates and other pipeline assets are being evaluated to target areas of unmet needs. Its product candidates include AKB-9090, AKB-10108, AKB-097 and praliciguat.

  • Revenue in USD (TTM)225.07m
  • Net income in USD-15.91m
  • Incorporated2007
  • Employees181.00
  • Location
    Akebia Therapeutics Inc245 First StreetCAMBRIDGE 02142United StatesUSA
  • Phone+1 (617) 871-2098
  • Fax+1 (617) 871-2099
  • Websitehttps://akebia.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.